Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector
Sort by: Date|Relevance

Relmada Therapeutics Stock Soars on Phase 2 Depression Study Results

Shares of Relmada Therapeutics have traded wildly today after it announced Phase 2 results for its anti-depressant drug dextromethadone. The firm's shares have traded 100–200% higher today and the stock was halted several times trading due to extreme price volatility. ...
Streetwise Reports | October 16, 2019 |

Intra-Cellular Therapies Shares Rise 200% on FDA Approval of Adult Schizophrenia Drug

Shares of Intra-Cellular Therapies opened greater than 100% higher today after the company reported that the FDA approved its antipsychotic CAPLYTA® (lumateperone) drug for the treatment of schizophrenia in adults. This morning a biopharmaceutical company foc...
Streetwise Reports | December 27, 2019 |

T2 Biosystems Shares Nearly Double on Worldwide COVID-19 Testing License Deal

Shares of T2 Biosystems Inc. traded 90% higher after the company reported that a new COVID-19 assay licensed from Hackensack Meridian Health's Center for Discovery and Innovation will be adapted to run on its FDA-cleared T2Dx® Instrument. Diagnostic...
Streetwise Reports | March 26, 2020 |

Varta, Rock Tech Lithium, Millennial Lithium - all signs point to growth

ON THE AUTHOR: Carsten Mainitz The native Rhineland-Palatinate has been a passionate market participant for more than 25 years. After studying business administration in Mannheim, he worked as a journalist, in equity sales and many years in equity research. Most r...
Carsten Mainitz | March 23, 2021 |

East-West Trade War: Never Take a Knife to a Gunfight

It's a funny thing that happens when the stress of financial insolvency bubbles up to the surface. Decisions once considered "routine" (like brushing one's teeth or walking one's dog) suddenly have life-or-death outcomes, complete with cold sweats, sleepless nights and ...
Streetwise Reports | October 11, 2019 |

Dissecting the Stock Bubble Debate: Flow Versus Value

"For every action, there is an equal and opposite reaction." —Sir Isaac Newton (Newton's Third Law) In nature, where everything moves freely absent human interference, her omnipotent forces are allowed to manifest themselves in manners that create a living ecosystem t...
Streetwise Reports | November 19, 2019 |

The Only 'Bubble' That Counts

Ever since Sept. 19, 2008, when Hammerin' Hank Paulson appeared in front of the U.S. Congress on bended knee and begged those clueless politicians for a bailout—which he did successfully—the spread of moral hazard throughout the world has been a contagion that makes the...
Streetwise Reports | January 21, 2020 |

Datable's Multi-Channel Rewards Program Converts Data into Dollars with Its Loyal Customers,...

Datable's Multi-Channel Rewards Program Converts Data into Dollars with Its Loyal Customers, Top Line Revenue Expected to More Than Double for 2020 Having attracted major brands such as Universal Pictures, Fandango and Toro to its consumer loyalty and rewards pla...
Streetwise Reports | February 26, 2020 |

Building a Better Covid-19 Antibody Test

ProMIS is harnessing its unique technology platform to develop a more error-free antibody test. Testing has been an Achilles heel of the coronavirus pandemic, but ProMIS Neurosciences Inc. (PMN:TSX; ARFXF:OTCQB) has partnered with Dr. Hans Frykman and the ...
Streetwise Reports | May 7, 2020 |

Weimar Fed in the Twenty-First Century

I was pacing around the house this lovely but cold Friday afternoon (after finally having the water supply restored after our well filed for unemployment benefits), trying desperately to think of a topic to write about in this weekly missive, when it suddenly occurred t...
Streetwise Reports | May 15, 2020 |
1 2 3 4 5 6 7 8 9 10 ...